Not exact matches
The trial investigated the drug in two separate cohorts of patients: Cohort A, which included 170 patients with heavily pretreated metastatic triple negative breast cancer (mTNBC) regardless of PD - L1
expression, and Cohort B, which included 52 patients with PD - L1 -
positive tumors who received it as first - line therapy.
When the team analyzed tissues from 261 patients with NSCLC, they found an inverse correlation between the two molecules; that is, more than 80 percent of patient tissues with low levels of the
tumor suppressing C / EBPα were
positive for BMI1
expression.
The authors looked at gene
expression in a panel of 50 ERBB2 (Her2)
positive breast
tumors and found that this pattern held up: DNA hypomethylation is associated with decreased gene
expression in breast cancer.
A, HIF - 1α and Glut1
expression in ER - α —
positive (i) and negative (ii) xenografts compared with
tumor size (mm3).